Laevoroc Oncology Emerges from Stealth Mode Announcing Seed Financing and Acquisition of Worldwide Patents to Oral Gemcitabine Prodrug

Zug, Switzerland, 11 May 2021: Laevoroc Oncology (‘Laevoroc’ or ‘the company’), a privately owned, Swiss oncology development group of companies, launched today announcing successful completion of seed financing with private and individual investors, raising over USD 1.1 million. The Company also announces the acquisition of worldwide patents (excluding China) for an oral prodrug form of gemcitabine, one of the most important chemotherapy agents worldwide.

Read full release here